Under Bristol-Myers Squibb’s (BMY) established brands, the sales of Baraclude fell from $264.0 million in the third quarter of 2017 to $175.0 million in the third quarter of 2018 due to lower demand resulting from heightened competition.
Sustiva and Reyataz sales fell from $183.0 million and $174.0 million, respectively, in the third quarter of 2017 to $72.0 million and $87.0 million, respectively, in the third quarter of 2018. Sales from its other brands also witnessed a fall from $539.0 million in the third quarter of 2017 to $382.0 million in the third quarter of 2018.
Bristol-Myers Squibb stock corrected from $68.96 on February 16 to $50.53 on May 8. Subsequently, it steadily recovered to $63.23 on October 9.
Amid broader market turmoil in October, Bristol-Myers Squibb stock saw selling pressure, and it fell to $48.83 on October 24. After posting a strong financial performance in the third quarter, the company has seen buying interest in its shares in the last few trading sessions.
Bristol-Myers Squibb’s EV (enterprise value) is $84.07 billion, and its EV-to-revenue ratio is 3.89. The stock is trading at a forward PE multiple of 12.49x. Its price-to-sales ratio is 3.68, and its price-to-book ratio is 5.95. In comparison, the price-to-book ratios of its peers Eli Lilly and Company (LLY), Merck & Co. (MRK), and Pfizer (PFE) are 9.57, 5.90, and 3.64, respectively.
We’ll take a look at analysts’ views on Bristol-Myers Squibb stock in the next article.